Clinical Trials

Sponsor(s): Technische Universität München, Else Kröner Fresenius Foundation, Unilever-Stiftung, Milupa GmbH

Condition(s):

Breast lump
Obesity
Pregnancy

Purpose: Pregnant and lactating women receive n-3 fatty acids starting from week 15 of gestation until 4 months post-partum (pp) in comparison to a control group, who only gets information about adequately healthy nutrition during pregnancy and lactation. The amount of fat in newborns is measured through skinfold thickness, ultrasound, and magnetic resonance imaging (MRI). It is hypothesised that a reduction in arachidonic acid intake and an increase of n-3 LC PUFAs (long chain polyunsaturated fatty acids) via supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) could lead to less expansive fat tissue development in the first year of life.

Eligibility:

Minimum Age:

18 Years

Maximum Age:

43 Years

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

- Gestational age <= 15th week of gestation

- Age: 18-43 years

- Written informed consent

- Body mass index (BMI) before pregnancy between 18 and 30 km/m2

Exclusion Criteria:

- High risk pregnancy

- Hypertonus

- Chronic diseases (i.e. diabetes mellitus)

- Psychiatric diseases

- Former supplementation with LC-PUFA

Other Location(s): Munich, Germany

Terms: This is an abstract courtesy of ClinicalTrials.gov, a service of the US National Institute of Health Developed by the National Library of Medicine. ClinicalTrials.gov provides regularly updates information about federally and privately supported clinical research in human volunteers.